Publications by authors named "J-F Shu"
Article Synopsis
- Dual immune checkpoint blockade (ICB) using CTLA4 and PD-(L)1 inhibitors shows improved anti-tumor effectiveness and immune toxicity compared to PD-(L)1 inhibitors alone in advanced non-small-cell lung cancer (NSCLC) patients.
- Patients with mutations in STK11 and/or KEAP1 genes benefit more from the combination treatment compared to those receiving only PD-(L)1 inhibitors, as shown in the POSEIDON trial.
- The loss of KEAP1 serves as a strong predictor for the success of dual ICB, as it leads to a more favorable outcome by changing the tumor's immune environment to better engage CD4 and CD8 T cells for anti-tumor activity. *
Single-Cell RNA Sequencing Deconstructs the Distribution of Immune Cells Within Abdominal Aortic Aneurysms in Mice.
Arterioscler Thromb Vasc Biol
September 2024
Article Synopsis
- The study investigates the role of immune cells in the development of abdominal aortic aneurysm (AAA) through single-cell RNA transcriptomic analysis, revealing distinct immune cell subsets in AAA compared to normal aorta tissues.* -
- Significant findings include the exclusive presence of conventional dendritic cell type 1 in AAA tissue and the identification of specific intercellular communication pathways that may promote AAA development.* -
- Overall, the research highlights a complex inflammatory microenvironment in AAA, suggesting that understanding these interactions could lead to new treatment strategies for patients.*
Article Synopsis
- A phase 3b clinical trial was conducted to compare the effectiveness and safety of risankizumab and ustekinumab in patients with moderate-to-severe Crohn's disease who didn't respond to anti-TNF therapy.
- The study evaluated two primary outcomes: clinical remission at week 24 and endoscopic remission at week 48, with risankizumab being tested for noninferiority and superiority, respectively.
- Results showed that risankizumab was not only noninferior to ustekinumab for clinical remission but also superior for endoscopic remission, with significant improvements reported in patients receiving risankizumab.
Article Synopsis
- PD-1 inhibitors show limited effectiveness on their own for treating hepatocellular carcinoma (HCC), but a new personalized therapeutic cancer vaccine (PTCV) may boost their efficacy by enhancing immune responses against tumors.
- In a study, a DNA plasmid PTCV combined with pembrolizumab was tested on patients with advanced HCC; the treatment was found to be relatively safe with manageable side effects and showed a 30.6% objective response rate.
- The study observed that patients with more neoantigens from the vaccine had better clinical responses, with immune profiling revealing a strong T cell response directed at tumor cells, supporting the vaccine's potential as a viable therapeutic approach.
Background: Small, randomized trials of patients with cervical artery dissection showed conflicting results regarding optimal stroke prevention strategies. We aimed to compare outcomes in patients with cervical artery dissection treated with antiplatelets versus anticoagulation.
Methods: This is a multicenter observational retrospective international study (16 countries, 63 sites) that included patients with cervical artery dissection without major trauma.
Background: Cerebral cavernous malformation with symptomatic hemorrhage (SH) are targets for novel therapies. A multisite trial-readiness project (https://www.clinicaltrials.
View Article and Find Full Text PDFBackground: Quantitative susceptibility mapping (QSM) and dynamic contrast-enhanced quantitative perfusion (DCEQP) magnetic resonance imaging sequences assessing iron deposition and vascular permeability were previously correlated with new hemorrhage in cerebral cavernous malformations. We assessed their prospective changes in a multisite trial-readiness project.
Methods: Patients with cavernous malformation and symptomatic hemorrhage (SH) in the prior year, without prior or planned lesion resection or irradiation were enrolled.
Article Synopsis
- Neoadjuvant immunotherapy may help achieve long-term tumor remission by boosting the body's immune responses before tumor removal, and this study explores the role of tertiary lymphoid structures (TLS) in this process for liver cancer (HCC).
- The research found that neoadjuvant immunotherapy not only promotes the formation of TLS but also correlates with better treatment outcomes, including higher levels of T and B cells and improved disease-free survival.
- Notably, the study observed that as tumors regress, TLS undergo changes that indicate continued immune activity and contribute to T cell memory, which may be crucial for long-term immunity against cancer.
Anti-PD-1/PD-L1 immunotherapy has achieved impressive therapeutic outcomes in patients with multiple cancer types. However, the underlined molecular mechanism(s) for moderate response rate (15-25%) or resistance to PD-1/PD-L1 blockade remains not completely understood. Here, we report that inhibiting the deubiquitinase, USP8, significantly enhances the efficacy of anti-PD-1/PD-L1 immunotherapy through reshaping an inflamed tumor microenvironment (TME).
View Article and Find Full Text PDFBackground: A small randomized controlled trial suggested that dabigatran may be as effective as warfarin in the treatment of cerebral venous thrombosis (CVT). We aimed to compare direct oral anticoagulants (DOACs) to warfarin in a real-world CVT cohort.
Methods: This multicenter international retrospective study (United States, Europe, New Zealand) included consecutive patients with CVT treated with oral anticoagulation from January 2015 to December 2020.
Background: In acute ischemic stroke, there is uncertainty regarding the benefit and risk of administering intravenous alteplase before endovascular thrombectomy.
Methods: We conducted a trial at 41 academic tertiary care centers in China to evaluate endovascular thrombectomy with or without intravenous alteplase in patients with acute ischemic stroke. Patients with acute ischemic stroke from large-vessel occlusion in the anterior circulation were randomly assigned in a 1:1 ratio to undergo endovascular thrombectomy alone (thrombectomy-alone group) or endovascular thrombectomy preceded by intravenous alteplase, at a dose of 0.